Latest News - Glaukos Corporation

Wednesday, February 22, 2017 | Management/Leadership, Glaukos Corporation

L. Jay Katz, MD, Joins Glaukos Corporation as Chief Medical Officer

Glaukos announced that L. Jay Katz, MD, FACS, has joined the company as Chief Medical Officer. Dr. Katz is currently a practicing ophthalmologist, the Director of Glaucoma Service at Wills Eye Hospita…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Monday, February 06, 2017 | Management/Leadership, Glaukos Corporation

Joseph Gilliam to Join Glaukos Corporation as Chief Financial Officer and Senior Vice President of Corporate Development

Glaukos announced that Joseph E. Gilliam will join the company as Chief Financial Officer and Senior Vice President, Corporate Development in May 2017. Mr. Gilliam will replace the company’s cur…

Read the full story

Thursday, February 02, 2017 | Management/Leadership, Glaukos Corporation

Glaukos Corporation Promotes Chris M. Calcaterra to Chief Operating Officer

Glaukos Corporation announced that Chris M. Calcaterra has been named Chief Operating Officer, effective immediately. Mr. Calcaterra joined Glaukos in 2008 and has served as its Chief Commercial Offic…

Read the full story

Monday, December 12, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

Study Published in Journal of Glaucoma Evaluates a Single Glaukos iStent Trabecular Micro-Bypass Stent as a Standalone Procedure

Glaukos Corporation announced that a study published recently in the Journal of Glaucoma showed that a single iStent Trabecular Micro-Bypass Stent significantly reduced IOP when implanted as a standal…

Read the full story

Tuesday, November 08, 2016 | Clinical Trials, Glaucoma, Medical Studies, Glaukos Corporation

New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject Trabecular Micro-Bypass in Standalone Procedure

Glaukos announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open angle glaucoma achieved a ≥ 20% reduction in unmedicated IOP 1 year after implantation of the iS…

Read the full story

Monday, October 31, 2016 | Clinical Trials, Glaucoma, Glaukos Corporation

Report: iStent Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population

Glaukos Corporation announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean IOP of 12.9 mm Hg and a 61% decrease in m…

Read the full story

Tuesday, September 27, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

New Study Underscores Ability of iStent to Achieve Sustained Reductions in IOP and Medication Use

A study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma (OAG) eyes receiving the iStent Trabecular Micro-Bypass Stent in combination with cataract surger…

Read the full story

Friday, September 23, 2016 | Glaucoma, Medical Studies, Glaukos Corporation

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Glaukos announced that an international study published in Ophthalmology and Therapy showed that newly diagnosed primary open-angle glaucoma patients achieved a 43% reduction in mean IOP to 14.6 mm Hg…

Read the full story

Tuesday, September 06, 2016 | Conferences, Glaukos Corporation

Multiple Surgeons to Present Clinical Data Regarding Glaukos Glaucoma Devices at 2016 European Society of Cataract and Refractive Surgeons Congress

Glaukos announced that clinical data regarding its products will be presented in 12 key opinion leader (KOL) podium and poster presentations at the annual Congress of the European Society of Cataract …

Read the full story

Thursday, April 28, 2016 | Conferences, Glaucoma, Glaukos Corporation

Glaukos Featured in Numerous Presentations at 2016 American Society of Cataract and Refractive Surgery

Glaukos announced that its products will be featured in numerous presentations at the annual American Society of Cataract and Refractive Surgery (ASCRS) meeting being held at the Ernest N. Morial Conv…

Read the full story

Tuesday, April 19, 2016 | Earnings & Financials, Glaukos Corporation

Glaukos to Release First Quarter 2016 Financial Results After Market Close on May 3

Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …

Read the full story

Friday, April 15, 2016 | Glaucoma, Management/Leadership, Glaukos Corporation

Glaukos Announces Retirement of Olav Bergheim from Board of Directors

Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …

Read the full story

Monday, March 28, 2016 | Glaucoma, Glaukos Corporation

Glaukos iStent Trabecular Micro-Bypass Stent Approved in Japan

Glaukos announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the iStent Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of…

Read the full story

Monday, February 08, 2016 | Product Releases, Glaukos Corporation

Glaukos Establishes Direct Sales Organization and Launches iStent inject Trabecular Micro-Bypass Stent in Australia

Glaukos Corporation announced that it has established a direct sales organization and launched the iStent inject Trabecular Micro-Bypass Stent in Australia, according to a company news release. The…

Read the full story
Load More